Acquisition Accelerates AstraZeneca's Biologics Strategy

Article

AstraZeneca (London, UK, www.astrazeneca.com) has entered into a definitive agreement to acquire MedImmune, Inc. (Gaithersburg, MD, www.medimmune.com), in an all-cash transaction.

AstraZeneca (London, UK, www.astrazeneca.com) has entered into a definitive agreement to acquire MedImmune, Inc. (Gaithersburg, MD, www.medimmune.com), in an all-cash transaction. Under the terms of the agreement, AstraZeneca will acquire all of the fully diluted shares of MedImmune common stock at a price of $58 per share, for a total consideration of approximately $15.6 billion (including approximately $340m net cash). 

The combination of MedImmune with AstraZeneca’s wholly-owned subsidiary Cambridge Antibody Technology (CAT) will create a fully integrated biologics and vaccines business within the AstraZeneca Group with critical mass in research, development, regulatory, manufacturing, and global sales and marketing reach.

The acquisition extends AstraZeneca’s R&D science base to allow it to address novel drug targets through 3 key technological approaches: small molecules, biologics and, for the first time, vaccines. The deal increases the proportion of biologics in AstraZeneca’s pipeline from 7 percent to 27 percent and enlarges the total pipeline by 45 projects to 163 projects. The deal is expected to close in June 2007.

Recent Videos
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Daniel Fischer, Tevard
Related Content
© 2025 MJH Life Sciences

All rights reserved.